EpiAxis Therapeutics, a leading LSD1 company with a focus on the treatment, diagnosis and monitoring of cancer and the prevention of its recurrence, is presenting at Biotech Showcase™ 2023.

EpiAxis CEO Dr Jeremy Chrisp will discuss the company’s focus on developing novel cancer treatments and the prevention of cancer recurrence.

EpiAxis’ lead therapeutic program targets the epigenetic eraser enzyme lysine-specific demethylase 1 (LSD1) using a novel dual mechanism that targets the dormant cancer cells that seed cancer recurrence and, concurrently reinvigorates exhausted immune cells for improved cancer clearance.

“Our Phase 1 proof of concept study has validated LSD1 as a target and confirms inhibition of LSD1 reprograms cancer cells,” Dr Chrisp said.

“We have dominant intellectual property across our first-in-class assets covering targeting of LSD1 in combination with surgery, other drugs including chemotherapy, immuno-therapy, radiotherapy across the metastatic setting.”

In 2022, EpiAxis signed a material transfer agreement with Seattle Children’s Research Institute that will help researchers study a new approach to treating paediatric brain cancer. It also entered a collaboration with University Health Network (UHN) – Canada’s largest and leading research hospital – to study a new approach to prostate cancer treatment.

EpiAxis is also collaborating with Peptilogics to leverage AI for drug discovery to inhibit epigenetic oncology targets, aiming to reprogram cancer cells and drive immune reinvigoration.

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.

“We are delighted that EpiAxis Therapeutics will be joining us in San Francisco and presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton.

“Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”

To learn more about EpiAxis Therapeutics please contact:

Dr Jeremy Chrisp

Phone: +61 421 012 268